Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Wen-Quan Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109384654. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 6 papers · 2019: 6 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 21

  1. Clinical subtypes of stage IV pancreatic ductal adenocarcinoma: a new perspective of clinical practices. Co-author DOI 10.1007/s10555-025-10295-x↗
  2. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i8.828↗
  3. Angiogenesis in pancreatic cancer: current research status and clinical implications. Co-author DOI 10.1007/s10456-018-9645-2↗
  4. Reflections on depletion of tumor stroma in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2019.01.007↗
  5. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2018.10.539↗
  6. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. First author DOI 10.2174/0929867325666180413101722↗
  7. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. First author DOI 10.7150/jca.30883↗
  8. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Co-author DOI 10.7150/jca.32072↗
  9. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.hbpd.2018.03.007↗
  10. Guidelines for the diagnosis and treatment of pancreatic adenocarcinoma (2018 edition): A standardized procedure recommended in China. Co-author DOI 10.1016/j.hbpd.2018.07.004↗
  11. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  12. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6737-6↗
  13. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Co-author DOI 10.3892/ijo.2018.4269↗
  14. The Significance of Liquid Biopsy in Pancreatic Cancer. Co-author DOI 10.7150/jca.24591↗
  15. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.08.005↗
  16. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… First author DOI 10.1038/srep19222↗
  17. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Co-author DOI 10.18632/oncotarget.6819↗
  18. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000000751↗
  19. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Co-author DOI 10.1007/s00259-014-2688-8↗
  20. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic canc… Co-author DOI 10.1371/journal.pone.0071189↗
  21. Significance of caveolin-1 regulators in pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.8.4501↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 19 shared papers, 2013–2020 · strength 1.42
  2. Liang Liu · 18 shared papers, 2013–2020 · strength 1.38
  3. Huaxiang Xu · 17 shared papers, 2013–2020 · strength 1.16
  4. Chuntao Wu · 16 shared papers, 2013–2020 · strength 1.10
  5. Shi-Rong Zhang · 10 shared papers, 2018–2019 · strength 0.83
  6. Jin-Zhi Xu · 9 shared papers, 2018–2019 · strength 0.77
  7. He-Li Gao · 9 shared papers, 2018–2020 · strength 0.74
  8. Zi-Hao Qi · 8 shared papers, 2016–2019 · strength 0.58
  9. Shuo Li · 5 shared papers, 2018–2020 · strength 0.43
  10. Jin Xu · 7 shared papers, 2013–2019 · strength 0.39
  11. Yifei Zhang · 1 shared paper, 2025 · strength 0.37
  12. Liang Liu · 1 shared paper, 2025 · strength 0.37
  13. Jiang Long · 6 shared papers, 2013–2018 · strength 0.31
  14. Chen Liu · 6 shared papers, 2013–2018 · strength 0.31
  15. Hao Li · 3 shared papers, 2018–2019 · strength 0.28
  16. Quanxing Ni · 3 shared papers, 2018 · strength 0.26
  17. Wei Jin · 3 shared papers, 2018–2019 · strength 0.23
  18. Shuai-Shuai Xu · 2 shared papers, 2019–2020 · strength 0.18
  19. Jin-Feng Xiang · 3 shared papers, 2016–2017 · strength 0.17
  20. Xian-Jun Yu · 1 shared paper, 2018 · strength 0.11
  21. Min Li · 2 shared papers, 2016 · strength 0.10
  22. Tao Chen · 2 shared papers, 2014–2015 · strength 0.10
  23. Wang Jiang · 1 shared paper, 2020 · strength 0.10
  24. Shuo Li · 1 shared paper, 2019 · strength 0.08
  25. Hao Li · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.